Sequential Mitochondrial Transplantation for Myocardial Ischemia-Reperfusion Injury Treatment

Area of Science:

• Cardiology
• Biomedical Engineering
• Regenerative Medicine

Background:

• Myocardial ischemia-reperfusion injury (IRI) causes significant cardiac dysfunction due to mitochondrial damage and energy deficits.
• Current treatments for IRI lack effective strategies to address mitochondrial dysfunction and sustain energy supply.
• Restoring mitochondrial function and energy homeostasis is critical for cardiac recovery post-IRI.

Purpose of the Study:

• To develop a novel sequential administration approach for mitochondrial transplantation to treat myocardial IRI.
• To engineer mitochondria with nanomotors for targeted accumulation in damaged cardiac tissue.
• To enhance cardiac function and reduce adverse effects associated with mitochondrial transplantation in IRI.

Main Methods:

• Engineered mitochondrial nanomotors were created by modifying mitochondria with chemotactic nanomotors and denatured bovine serum albumin.
• Mitochondria were administered sequentially: immediate intramyocardial injection followed by intravenous injection.
• The targeting mechanism involved neutrophils and nanomotor chemotaxis to the inflamed cardiac tissue.

Main Results:

• Sequential administration of engineered mitochondria stabilized energy supply and rescued cardiomyocytes from IRI.
• Intravenous administration in the repair stage continuously supplemented energy, enhancing cardiac function.
• In vivo studies demonstrated reduced adverse reactions like arrhythmia compared to high-dose transplantation.

Conclusions:

• Sequential administration of engineered mitochondria is a promising strategy for treating myocardial IRI.
• This approach effectively targets the inflammatory microenvironment of IRI, improving energy supply and cardiac function.
• The method enhances the clinical translation potential of mitochondrial transplantation for cardiac repair.